Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Pennsylvania Genentech |
---|---|
Information provided by: | University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT00472693 |
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
Condition | Intervention | Phase |
---|---|---|
Breast Cancer |
Drug: Bevacizumab, Abraxane |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-Line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer |
Estimated Enrollment: | 37 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jessica Genewski, BSN | 215-662-6388 | jessica.genewski@uphs.upenn.edu |
United States, Pennsylvania | |
Abramson Cancer Center at University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 |
Principal Investigator: | Angela DeMichele, M.D. | Abramson Cancer Center of University of Pennsylvania |
Responsible Party: | University of Pennsylvania Abramson Cancer Center ( Angela DeMichele, M.D. ) |
Study ID Numbers: | UPCC 02106 |
Study First Received: | May 11, 2007 |
Last Updated: | April 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00472693 |
Health Authority: | United States: Institutional Review Board |
Breast cancer Metastatic breast cancer Second-Line Therapy Triple Negative |
Her-2 negative Hormone receptor negative Abraxane Bevacizumab |
Skin Diseases Paclitaxel Breast Neoplasms Bevacizumab Breast Diseases |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Mitosis Modulators Antimitotic Agents Angiogenesis Inhibitors Pharmacologic Actions |
Neoplasms Neoplasms by Site Therapeutic Uses Tubulin Modulators Growth Inhibitors Angiogenesis Modulating Agents Antineoplastic Agents, Phytogenic |